Author Archive

ATHX data due April 19. HALO to initiate Phase 3 PEGPH20 in 1Q 2016 + updates for PTLA DSCO GLYC OCUL PFNX PVCT SRNE

Apr 09, 2015 No Comments

Latest updates to the Company Pipeline Database for April 6-8. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ATHX 3.12 Multistem Ischemic stroke Phase 2 Initiated 3Q 2011. Enrolment completed late Dec 2014. Initial data due April 19 2015 HALO 15.28 PEGPH20 Cancer – pancreatic Phase 2 Clinical hold lifted June […]

Read more

Updates for DYAX HRTX MDVN NDRM OCRX PRTK RPRX SAGE XENE XOMA

Apr 03, 2015 No Comments

Latest updates to the Company Pipeline Database for April 1 and 2. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary DYAX 27.05 DX-2930 Hereditary angioedema (HAE) Phase 2 Positive Phase 1b data released late March 2015. HRTX 14.07 APF530 – Sustol Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV) […]

Read more

TTNP data due 2Q. VRTX Adcom date set +updates for CAPR GWPH VTAE

Apr 01, 2015 No Comments

Latest updates to the Company Pipeline Database for March 31. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary CAPR 8.70 Cenderitide Ambulatory heart failure Phase 2 Phase 2 enrolment completed late March 2015. Topline data due 2H 2015 GWPH 91.13 Epidiolex Dravet Syndrome Phase 2/3 Top line Phase 3 data expected […]

Read more

BDSI and CANF fail trials. AMGN granted priority review + ARGS update

Mar 31, 2015 No Comments

Latest updates to the Company Pipeline Database for March 30. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text AMGN 164.30 Kyprolis Relapsed multiple myeloma – patients who have received at least one prior therapy sNDA filing sNDA PDUFA priority review July 26, 2015 ARGS 9.52 AGS-003 ADAPT Trial mRCC Phase […]

Read more

Latest updates for ADMP ALDX CARA CNAT HTBX NEOT NERV OGXI OHRP ONTX OTIC PSDV ASND DERM EBS FWP LJPC LXRX RARE VBLT ZSAN

Mar 28, 2015 No Comments

Latest updates to the Company Pipeline Database for March 25-27. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ADMP 5.39 Epinephrine PFS Anaphylaxis CRL CRL issued March 27 2015 3/29/2015 ALDX 28.43 NS2 Noninfectious anterior uveitis Phase 2 Phase 2 initiated late March 2015. Preliminary due by end of […]

Read more

AERI Phase 3 data due mid 2Q 2015 + updates for ALDX LPCN LPTN MSTX

Mar 25, 2015 No Comments

Latest updates to the Company Pipeline Database for March 24. Refer to the FDA Calendar for upcoming catalysts: AERI 31.08 Rhopressa Glaucoma Phase 3 Phase 3 Rocket 1 trial data due mid-2Q 2015. Rocket 2 data due 3Q 2015 3/25/2015 ALDX 10.62 NS2 Sjögren-Larsson Syndrome (SLS) Phase 2 Phase 3 initiated March 2015. Prelim data due by […]

Read more

MEIP fails Phase 2 trial + updates for BLRX CHRS VRTX DERM

Mar 24, 2015 No Comments

Latest updates to the Company Pipeline Database for March 23. Refer to the FDA Calendar for upcoming catalysts: BLRX 2.10 BL-8040 Cancer – Acute myeloid leukemia (AML) Phase 2a Phase 2a enrolment began Jun 2013. Partial data released Dec 2013. Full data 2H 2015 3/24/2015 CHRS 25.60 CHS-1420 Psoriasis Phase 3 Phase 3 planned for 2Q 2015, […]

Read more

Latest biotech updates for week ended March 20

Mar 22, 2015 No Comments

Latest updates to the Company Pipeline Database for the week ending March 20. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ACRX 4.15 ARX-04 Moderate-to-severe acute pain Phase 3 Phase 3 trial initiated March 2015. Data due 4Q 2015 3/22/2015 ANTH 4.34 Blisibimod Lupus Phase 3 Missed primary endpoints […]

Read more

Updates for ACAD ANAC BIND BSTC CCXI CNAT CTIC CYTK EBIO EGLT FATE HRTX MRNS OCRX PLX PPHM SNTA SPPI TBPH TKAI TKMR XENE ZSPH

Mar 14, 2015 No Comments

Latest updates to the Company Pipeline Database. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ACAD 34.45 Pimavanserin Parkinson’s disease psychosis (PDP) Phase 3 NDA filing of Pimavanserin for Parkinson’s disease psychosis (PDP) due 2H 2015 3/14/2015 ANAC 55.66 AN2728 Mild-to-moderate atopic dermatitis Phase 3 Phase 3 […]

Read more

Updates for ADHD AKBA CYTR OCUL RDUS TBPH VSTM

Mar 11, 2015 No Comments

Latest updates to the Company Pipeline Database. Refer to the FDA Calendar for upcoming catalysts: ADHD 7.12 MDX (Metadoxine Extended Release (MG01CI)) Pediatric ADHD Phase 2b Phase 2b data released March 2015. No safety concerns but analyses of secondary cognitive measures did not produce statistically significant results 3/11/2015 AKBA 11.43 AKB-6548 Anemia related to chronic […]

Read more

SPPI PDUFA date set. KYTH Adcom approval. Setback for ACRX + updates for CTIC EDAP GLMD IMUC LGND SSH

Mar 10, 2015 No Comments

Latest updates to the Company Pipeline Database. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ACRX 5.51 ARX-04 Moderate-to-severe acute pain Phase 3 Phase 3 planned 3/10/2015 ACRX 5.51 Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery CRL CRL Jul 26 2014. […]

Read more